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ABSTRACT
Objective To investigate serum antibody reactivity
against a panel of post-translationally modiﬁed vimentin
peptides (PTMPs) in patients with early inﬂammatory
arthritis.
Methods A panel of PTMPs was developed. Microtitre
plates were coated with peptides derived from vimentin
that were identical in length and composition except at
one amino acid that was changed to introduce one of
three post-translational modiﬁcations (PTMs)—either a
citrullinated, carbamylated or acetylated residue. Sera of
268 treatment-naive patients with early inﬂammatory
arthritis and symptoms ≤3 months’ duration were
tested. Patients were assigned to one of three outcome
categories at 18-month follow-up (rheumatoid arthritis
(RA), persistent non-RA arthritis and resolving arthritis).
Results Antibodies against citrullinated, carbamylated
and acetylated vimentin peptides were detected in the
sera of patients with early inﬂammatory arthritis. The
proportion of patients seropositive for all antibody types
was signiﬁcantly higher in the RA group than in the
other groups. Anti cyclic citrullinated peptide (CCP)-
positive patients with RA had higher numbers of
peptides recognised and higher levels of antibodies
against those peptides, representing a distinct proﬁle
compared with the other groups.
Conclusions We show for the ﬁrst time that antibodies
against acetylated vimentin are present in the sera of
patients with early RA and conﬁrm and extend previous
observations regarding anticitrullinated and
anticarbamylated antibodies.
INTRODUCTION
Rheumatoid arthritis (RA) is characterised by the
presence of autoantibodies including those against
citrullinated proteins (ACPAs) that are of diagnostic
and prognostic relevance and have been implicated
in disease pathogenesis.1–4 Testing for these anti-
bodies is performed using the commercially avail-
able cyclic citrullinated peptide-2 (CCP-2) ELISA,
whereby patients’ sera are tested for reactivity
against synthetic CCP that is not present in the RA
joint.5 The sensitivities and speciﬁcities of this assay
range between 60–80% and 88–95%, respectively.5
Testing for ACPAs using other autoantigens such as
citrullinated ﬁbrinogen and mutated citrullinated
vimentin (MCV) is also possible although less fre-
quently performed in routine clinical practice.6
MCV assays use an isoform of vimentin that is
present in the RA joint, and their reported sensitiv-
ity and speciﬁcity are 82% and 98%, respectively.7
Antibodies against another post-translational modi-
ﬁcation (PTM), anticarbamylated protein anti-
bodies, have recently been identiﬁed in the sera of
patients with RAwhere they have a prognostic role.8
It is thus possible that antibodies against further
PTMPs are present in the sera of patients with RA.
PTMs are common biological processes generat-
ing structural and functional diversity in an other-
wise limited proteome.9 Acetylation is a reversible
enzymatic process where acetyl groups are added to
free amines of lysine residues. Citrullination is an
enzymatic process, catalysed by peptidylarginine
deiminases (PADIs) that deiminate arginine to
citrulline. In contrast, carbamylation is a
non-enzymatic process that generates homocitrul-
line when cyanate ions react with amino groups of
lysines and arginines. Citrulline and homocitrulline
are structurally very similar, differing only by one
carbon atom that makes the homocitrulline side
chain longer (see online supplementary ﬁgure
S1A).10 Acetylated lysine is identical to homocitrul-
line except at the side chain terminal amine, which
is replaced by a methyl moiety.
PTMPs act as autoantigens in a variety of dis-
eases.11 Citrullination occurs during several bio-
logical processes and during inﬂammation. In RA,
citrullination takes place in the lungs, periodontal
tissue and synovium. Citrullinated proteins are
present in bronchoalveolar lavage ﬂuid, cells and
mucosa of smokers where they associate with
higher PADI2 levels. Furthermore, parenchymal
changes and citrullinated proteins have been identi-
ﬁed in the lungs of patients with early
ACPA-positive RA.12 13 This, together with exten-
sive data linking smoking to a higher susceptibility
of ACPA-positive RA, has led to the hypothesis that
long-term exposure to cigarette smoke may induce
citrullination of self-antigens leading to ACPA pro-
duction in susceptible individuals.14
Acetylation of lysine residues in histone proteins
plays a key role in nuclear transcription regulation.15
Acetylation of cytoplasmic proteins regulates enzym-
atic functions and metabolic pathways16 17 and is a
mechanism through which the microbiome can affect
its host.18 To date, there have been no studies of
immunity against acetylated peptides in RA.
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We investigated antibody reactivities against a panel of pep-
tides bearing one of three PTM in a well-characterised early
inﬂammatory arthritis patient cohort. We determined individual
immune responses in relation to the patient’s ﬁnal clinical
outcome to ascertain whether such analysis would help predict
RA development in patients with early synovitis. Additionally,
we sought to ﬁnd new clues to potential disease triggers.
PATIENTS AND METHODS
Patients
Patients were recruited to the Birmingham early arthritis cohort.
This is a cohort of disease-modifying antirheumatic drug
(DMARD)-naive patients with clinically apparent synovitis of
≥1 joint and inﬂammatory joint symptoms (morning stiffness
and/or inﬂammatory joint pain and/or swelling) of ≤3 months’
duration. Patients are assigned to an outcome category at
18-month follow-up. Outcomes include persistent RA (fulﬁlling
1987 American College of Rheumatology (ACR) criteria),19 per-
sistent non-RA arthritis and resolving arthritis. Resolving arth-
ritis was deﬁned as no clinically apparent joint swelling with no
DMARD or steroid use in the previous three months.
Classiﬁcation of patients into outcome groups using the 2010
ACR European League Against Rheumatism classiﬁcation
criteria20 was also performed. Data analyses according to these
criteria are shown in online supplementary ﬁgures S3–S5 and
tables S3 and S4. Sera of patients with symptom duration
>3 months at presentation were also tested.
Clinical and laboratory assessment
Demographic and clinical parameters including age, gender,
symptom duration, early morning stiffness duration, tender and
swollen joint counts, erythrocyte sedimentation rate, C reactive
protein, rheumatoid factor (RF) and anti-CCP status were
recorded. Anti-CCP antibody levels were determined using a
commercial anti-CCP2 assay (ELiA, Germany). Additional serum
samples were stored at −80°C for antibody panel analysis.
Post-translationally modiﬁed peptides panel
Antibodies against PTMP were determined by quantitative
immunometric enzyme immunoassay (Orgentec Diagnostika
GmbH, Germany). A panel of PTMP was developed speciﬁcally
for this purpose. Microtitre plates were precoated with strepta-
vidin followed by addition of biotinylated peptides of identical
length and composition that differed at one amino acid residue
( JPT, Germany). The control peptide was a 12 amino acid
sequence (GRVYATRSSAVR) derived from the vimentin protein
used in the MCV assay.7 Position 7 (denoted by an X in online
supplementary ﬁgure S1B) in this control peptide was changed
to add the relevant modiﬁcation. Thus, at position 7 the citrulli-
nated vimentin peptide had citrulline, the carbamylated peptide
had homocitrulline and the acetylated peptide had acetylated
lysine. Further details of this assay are provided in online sup-
plementary methods.
IgG and IgA antibodies against peptide panels were tested in
healthy individuals (n=160). Optical density values >98th per-
centile of the healthy controls were considered positive for all
antibodies. Online supplementary ﬁgure S2 shows the distribu-
tion of antibody levels in healthy individuals and patients.
Immunoblotting and competitions studies
Recombinant vimentin was citrullinated or carbamylated as pre-
viously described.7 8 For the acetylated isoform, albumin was
conjugated with the acetylated vimentin peptide as recombinant
vimentin is not stable after treatment with acetylation
reagents.21 Unmodiﬁed and modiﬁed vimentin proteins were
separated by SDS-PAGE, transferred to nitrocellulose and
used for the immunoblotting experiments. Sera from patients
with either triple (n=4) or double (n=5) reactivity were
used to verify the speciﬁcity of the antibodies under dena-
tured conditions. Sera were left untreated or preincubated
with 10 mg/mL of control vimentin peptide or peptides with
the relevant modiﬁcation. Bound antibodies were detected
by incubation with horseradish-peroxidase conjugated sec-
ondary antihuman IgG antibody (Dianova, Germany) and
visualised with an ECL detection system (GE Healthcare,
Germany).
Competition experiments using the immunoassay were also
performed. Sera of triple reactive patients (n=20) were sequen-
tially preincubated with the native (arginine containing) vimen-
tin peptide, each of the modiﬁed peptides or solvent from the
peptide stock solution (used as untreated control). All experi-
ments were run in triplicate. Resulting change in antibody
binding was analysed with each microtiter plate (citrullinated,
carbamylated and acetylated vimentin peptide). Data were calcu-
lated as percentage of residual binding relative to the solvent
treated (non-peptide containing) control. Further details of this
assay are provided in online supplementary methods.
Statistical analysis
All analyses were performed using PASW 20.0 (SPSS, USA).
Data were expressed as percentages, mean (±SD) or median
(IQR) as appropriate. Comparisons were performed with χ2,
analysis of variance and Kruskal–Wallis tests for categorical,
parametric continuous and non-parametric continuous data,
respectively. Post hoc analyses were performed with Sidack and
Dunn’s tests for parametric and non-parametric data, respect-
ively. Binary logistic regression was used to calculate ORs.
RESULTS
Serum samples from 268 patients with early arthritis were avail-
able. Patients were categorised into three clinical outcome
groups: RA (n=101), persistent non-RA arthritis (n=55) and
resolving arthritis (n=112). Demographic and clinical character-
istics of patients are represented in table 1, where patients with
RA have been subdivided into anti-CCP antibody-positive and
antibody-negative groups. The individual diagnosis of patients in
each outcome group is shown in online supplementary table S1.
Antibody seropositivity
The frequency of antibody seropositivity against different PTM
vimentin peptides is represented in ﬁgure 1. The proportion of
patients with positive IgG antibody tests was signiﬁcantly higher
in the RA group compared with persistent non-RA and resolving
arthritis groups for all modiﬁcations (p<0.001 for all). In con-
trast, the proportion of patients with a positive IgA antibody
test was signiﬁcantly higher in the RA group compared with the
others only for the citrullinated peptide (p=0.016).
Full-length vimentin immunoblotting and competition
studies
To conﬁrm that the results obtained with the immunometric
assay were representative of the in vivo situation where the full-
length vimentin protein is present, sera from four patients with
anti-CCP-positive RA that tested positive for IgG
anti-CitVimentin, anti-CarVimentin and anti-AcVimentin anti-
bodies (triple reactive) and ﬁve patients that tested positive for
IgG anti-CitVimentin and anti-CarVimentin (double reactive)
were analysed in full-length vimentin immunoblotting
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experiments (ﬁgure 2A and online supplementary ﬁgure S6).
Recombinant unmodiﬁed and modiﬁed vimentin proteins were
probed with non-preincubated sera and sera preincubated with
the native unmodiﬁed vimentin peptide or the modiﬁed pep-
tides sequentially. Reactivity against the whole protein could be
speciﬁcally blocked with a single dose of citrullinated, carbamy-
lated or acetylated peptide, respectively. Probing with non-
preincubated sera and preincubation with the unmodiﬁed
vimentin peptide had no blocking effect.
Next, we investigated whether reactivity in the immunoassay
could be blocked by preincubation of patients’ sera (n=20) with
the speciﬁc soluble peptides. Preincubation of patients’ sera with
the unmodiﬁed control vimentin peptide did not inhibit binding
for any of the antibodies (ﬁgure 2B). Preincubation of sera with
citrullinated, carbamylated and acetylated soluble peptides
blocked antibody reactivity in a dose-dependent manner
(ﬁgure 2C). To determine the degree of cross-reactivity between
the different antibody populations, competition experiments
were performed. Reactivity to anti-CitVimentin peptides was
blocked by preincubation with the soluble citrullinated peptide
as expected (70% inhibition), with weak inhibition of binding
by carbamylated (23%) and acetylated (17%) vimentin peptides
(ﬁgure 2D). Similar speciﬁcity and low cross-reactivity was
observed for the anti-AcVimentin antibodies. A degree of cross-
reactivity was observed for anti-CarVimentin antibodies where
32% of the binding was inhibited by preincubation with citrulli-
nated soluble peptide.
Sensitivity, speciﬁcity and predictive value of antibody
panel
To evaluate whether these antibodies would be a useful tool in
predicting RA development, sensitivity, speciﬁcity, positive and
negative predictive values for each antibody were calculated
(table 2). Using fulﬁlment of 1987 ACR criteria as the gold
standard, patients were grouped into two categories: RA and
non-RA (the latter comprising resolving and persistent non-RA
groups). Although some antibodies (eg, IgG anti-CarVimentin,
IgG anti-AcVimentin) showed high speciﬁcities, their sensitiv-
ities were low. The best sensitivity and speciﬁcity value combin-
ation was demonstrated by anti-CCP antibodies. Sensitivities of
the assays were greater when anti-CCP-positive RA was com-
pared with non-RA patients (table 3) as opposed to when
anti-CCP-negative RA was compared with non-RA patients
(table 4).
To assess the performance of these antibodies in patients with
longer disease duration, levels were measured in patients with
established RA and persistent non-RA arthritis presenting with
symptoms of >3 months’ duration. Here IgG anti-CarVimentin
and anti-AcVimentin antibodies showed 100% speciﬁcity
although sensitivities remained low (see online supplementary
table S2).
Table 1 Demographic, clinical and laboratory characteristics of patients in each outcome group
Anti-CCP-positive RA (n=48) Anti-CCP-negative RA (n=53) Persistent non-RA (n=55) Resolving arthritis (n=112) p-Value
Gender, n (%) 0.545
Female 30 (62.5) 26 (49.1) 30 (54.5) 58 (51.8)
Age (years) 53.1±13.4 60.3±15.8 49.4±19.4 45.5±15.9 <0.001
Disease duration (days) 57±22.7 58.9±21.2 54.1±22.1 45.79±21.4 0.001
CRP (mg/dL) 18 (6–40) 13 (6–41) 22 (8–38) 8 (0–20) <0.001
ESR (mm/hour) 29 (20–53) 23.5 (13–56) 25 (12–40) 14 (7–29) <0.001
DAS28 (CRP) 4.3±1.3 4.3±1.2 3.8±1.1 3.1±1.2 <0.001
DAS28 (ESR) 4.8±1.1 4.6±1.2 4.1±1.3 3.3±1.3 <0.001
Smoking, n (%) 0.01
Ever-smoker 27/47 (57.4) 32/51 (62.7) 19/53 (35.8) 42/103 (40.8)
Never-smoker 20/47 (42.6) 19/51 (37.3) 34/53 (64.2) 61/103 (59.2)
Anti-CCP positive, n (%) 48 (100) 0 (0) 1 (1.8) 2 (1.8) <0.001
RF positive, n (%) 40/46 (87.0) 8/52 (15.4) 5/54 (9.3) 12/109 (11.0) <0.001
Data are shown as number (percentage), mean±SD or median (IQR) as appropriate.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor.
Figure 1 Frequency of seropositivity for IgG and IgA antibodies
against different post-translationally modiﬁed peptides in rheumatoid
arthritis (RA) (dotted bars), persistent non-RA (black bars) and resolving
(grey bars) groups. (A) IgG antibody panel; (B) IgA antibody panel.
*p<0.05, ***p≤0.001.
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Figure 2 Competition studies. (A) Preincubation of post-translationally modiﬁed peptides with sera containing anticitrullinated, anticarbamylated
and antiacetylated antibodies speciﬁcally blocks full-length modiﬁed vimentin protein binding. Representative western blot image shown. In each
western blot, the following antigens were applied to the SDS-PAGE separation: lane 1, human recombinant vimentin; lane 2, citrullinated human
recombinant vimentin; lane 3, carbamylated human recombinant vimentin; lane 4, acetylated vimentin-albumin conjugate. (A) Immunoblot with
serum from a patients with rheumatoid arthritis (RA) cross-reacting with three different modiﬁed peptides. (B–D) Same experimental conditions as in
(A), but the serum was preincubated with 10 mg/mL of citrullinated vimentin (B), carbamylated vimentin (C) or acetylated isoform (D) for 2 h prior
to the immunoblotting experiment. Immunoassay competition experiments: (B) preincubation of patient sera with unmodiﬁed vimentin peptide did
not inhibit IgG binding for any of the antibodies tested. Control denotes non-preincubated sera. (C) Preincubation of sera with corresponding
modiﬁed peptides inhibited IgG binding in a dose-dependent manner. (D) Cross-reactivity between antibodies against different modiﬁcations.
Binding of IgG antibodies to anti-CitVimentin peptides is inhibited by preincubation with citrullinated vimentin predominantly with low degree of
inhibition by preincubation with carbamylated or acetylated vimentin. The same pattern is observed for anti-AcVimentin antibodies. Binding of
anti-CarVimentin IgG antibodies is predominantly inhibited by preincubation with carbamylated vimentin but inhibition is also observed when sera is
preincubated with citrullinated vimentin indicating a degree of cross-reactivity. Bars represent mean, error bars SD. CitVim, citrullinated vimentin
peptide; CarVim, carbamylated vimentin peptide; AcVim, acetylated vimentin peptide.
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Table 2 Sensitivity, specificity, positive predictive value and negative predictive value of antibody isotypes when comparing patients with RA
versus non-RA patients (persistent non-RA and resolving)
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Anti-CCP 47.5% (37.5% to 57.7%) 98.2% (94.8% to 99.6%) 94.1% (83.7% to 98.7%) 75.6% (69.3% to 81.1%)
Rheum factor
IgG 55.5% (45.2% to 65.3%) 92.2% (87.0% to 95.7%) 81.2% (69.9% to 89.6%) 77.4% (70.9% to 83.0%)
IgA 33.6% (24.6% to 43.8%) 91.0% (85.6% to 94.8%) 69.4% (54.6% to 81.8%) 69.4% (62.8% to 75.4%)
Anti-CitVimentin
IgG 56.4% (46.2% to 66.3%) 83.2% (76.7% to 88.6%) 67.1% (56.0% to 76.9%) 76% (69.1% to 81.9%)
IgA 43.6% (33.7% to 53.8%) 73.1% (65.6% to 79.6%) 49.4% (38.7% to 60.3%) 68.2% (60.8% to 74.9%)
Anti-CarVimentin
IgG 34.7% (25.5% to 44.8%) 94% (89.3% to 97.1%) 77.8% (62.9% to 88.9%) 70.4% (63.9% to 76.3%)
IgA 16.8% (10.1% to 25.6%) 88% (82.1% to 92.5%) 45.9% (29.5% to 63.1%) 63.6% (57.1% to 69.8%)
Anti-AcVimentin
IgG 36.6% (27.3% to 46.8%) 86.2% (80.1% to 91.1%) 61.7% (48.2% to 73.9%) 69.2% (62.5% to 75.4%)
IgA 35.6% (26.4% to 45.8%) 64.7% (56.9% to 71.9%) 37.9% (28.2% to 48.4%) 62.4% (54.8% to 69.7%)
AcVim, acetylated vimentin peptide; CarVim, carbamylated vimentin peptide; CitVim, citrullinated vimentin peptide; NPV, negative predictive value; PPV, positive predictive value; RA,
rheumatoid arthritis.
Table 3 Sensitivity, specificity, positive predictive value and negative predictive value of antibody isotypes when comparing patients with
anti-CCP-positive RA versus non-RA patients (persistent non-RA and resolving)
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Anti-CCP 100% (92.5% to 100%) 98.2% (94.8% to 99.6%) 94.1% (83.7% to 98.7%) 100% (97.8% to 100%)
Rheum factor
IgG 93.8% (82.8% to 98.6%) 92.2% (87.1% to 95.8%) 77.6% (64.7% to 87.5%) 98.1% (94.5% to 99.6%)
IgA 56.3% (41.2% to 70.5%) 91.0% (85.6% to 94.9%) 64.3% (48.0% to 78.4%) 87.9% (82.0% to 92.3%)
Anti-CitVimentin
IgG 93.8% (82.8% to 98.6%) 83.3% (76.7% to 88.6%) 61.6% (49.5% to 72.8%) 97.9% (93.9% to 99.5%)
IgA 62.5% (47.5% to 76.0%) 73.2% (65.6% to 79.6%) 40.0% (28.9% to 51.9%) 87.1% (80.4% to 92.2%)
Anti-CarVimentin
IgG 68.8% (53.8% to 81.3%) 94.0% (89.3% to 97.1%) 76.7% (61.4% to 88.2%) 91.3% (86.0% to 95.0%)
IgA 16.7% (7.5% to 30.2%) 88.0% (82.1% to 92.5% 28.6% (13.3% to 48.7%) 78.6% (72.0% to 84.3%)
Anti-AcVimentin
IgG 62.5% (47.5% to 76.0%) 86.2% (80.1% to 91.1%) 56.6% (42.3% to 70.2%) 88.9% (83.0% to 93.3%)
IgA 41.7% (27.6% to 56.8% 64.7% (56.9% to 71.9%) 25.3% (16.2% to 36.4%) 79.4% (71.6% to 85.9%)
AcVim, acetylated vimentin peptide; CarVim, carbamylated vimentin peptide; CitVim, citrullinated vimentin peptide; NPV, negative predictive value; PPV, positive predictive value; RA,
rheumatoid arthritis.
Table 4 Sensitivity, specificity, positive predictive value and negative predictive value of antibody isotypes when comparing patients with
anti-CCP-negative RA versus non-RA patients (persistent non-RA and resolving)
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
Anti-CCP 0.0% (0.0% to 6.8%) 98.2% (94.8% to 99.6%) 0.0% (0.0% to 69.5%) 75.6% (69.3% to 81.1%)
Rheum factor
IgG 20.8% (10.9% to 34.1%) 92.2% (87.1% to 95.8%) 45.8% (25.6% to 67.2%) 78.6% (72.2% to 84.1%)
IgA 13.2% (5.5% to 25.4%) 91.0% (85.6% to 94.9%) 31.8% (13.9% to 54.9%) 76.8% (70.3% to 82.5%)
Anti-CitVimentin
IgG 22.6% ((12.3% to 36.2%) 83.2% (76.7% to 88.6%) 30.0% (16.6% to 46.5%) 77.2% (70.4% to 83.2%)
IgA 26.4% (15.3% to 40.3%) 73.1% (65.6% to 79.6%) 23.7% (13.6% to 36.6%) 75.8% (68.4% to 82.2%)
Anti-CarVimentin
IgG 3.8% (0.6% to 13.0%) 94.0% (89.3% to 97.1%) 16.7% (2.6% to 48.4%) 75.5% (69.1% to 81.2%)
IgA 16.9% (8.1% to 29.8%) 88.0% (82.1% to 92.5%) 31.0% (15.3% to 50.8%) 76.9% (70.3% to 82.7%)
Anti-AcVimentin
IgG 13.2% (5.5% to 25.4%) 86.2% (80.1% to 91.1%) 23.3% (9.9% to 42.3%) 75.8% (69.1% to 81.7%)
IgA 30.2% (18.4% to 44.3%) 64.7% (56.9% to 71.9%) 21.3% (12.7% to 32.3%) 74.5% (66.6% to 81.4%)
AcVim, acetylated vimentin peptide; CarVim, carbamylated vimentin peptide; CitVim, citrullinated vimentin peptide; NPV, negative predictive value; PPV, positive predictive value; RA,
rheumatoid arthritis.
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Comparison of antibody proﬁles between outcome groups
To investigate the individual antibody proﬁles, the RA group
was subcategorised into anti-CCP-positive and anti-CCP-
negative as deﬁned by the anti-CCP2 assay. The frequency of
antibody seropositivity in the four outcome groups is repre-
sented in ﬁgure 3A, B.
To further investigate speciﬁc antibody reactivities, the
number of peptides recognised by patients in each outcome
group was determined. For IgG antibodies, there were clear
differences in the number of peptides recognised between
patients with anti-CCP-positive RA and the remaining groups
(ﬁgure 3C). While 58.3% of anti-CCP-positive patients had
antibodies recognising all three peptides, only small proportions
of patients in the anti-CCP-negative RA, persistent non-RA and
resolving groups (1.9%, 5.5% and 5.4%, respectively,
p<0.0001) recognised all three peptides. Conversely, while
73–80% of patients in the anti-CCP-negative, persistent non-RA
and resolving groups showed no reactivity to any of the pep-
tides, only 6.3% of anti-CCP-positive patients tested negative
for antibodies against these peptides (p<0.0001). A graphical
representation of the individual IgG antibody proﬁles of patients
in all outcome groups is shown in ﬁgure 4.
Characteristics of patients recognising all three peptides
containing post-translational modiﬁcations
The demographic and clinical characteristics of patients whose
sera tested positive for IgG antibodies against all three PTMP were
compared with the remaining patients. Anti-CCP and RF status
were the only signiﬁcant differences between groups (p<0.0001
for both). Logistic regression demonstrated that patients
with anti-CCP-positive RA were more likely to have positive
anti-CitVimentin (OR 60, 95% CI 19.6 to 183.5, p<0.0001),
anti-CarVimentin (OR 33, 95% CI 14.1 to 77.1, p<0.0001) and
anti-AcVimentin (OR 10.6, 95% CI 5.2 to 21.8, p<0.0001) anti-
bodies than patients with anti-CCP-negative RA.
DISCUSSION
We show that a range of IgG and IgA antibodies against
vimentin-derived PTMP are present in the sera of patients with
early inﬂammatory arthritis. In the context of IgG antibodies,
two distinct patterns arise, one for patients with anti-CCP-
positive RA and another for the remaining diagnostic categories.
Negligible reactivity to the unmodiﬁed control peptide was seen
across all groups, indicating that PTM of peptide is needed for
reactivity.
This is the ﬁrst description of anti-AcVimentin antibodies in the
sera of patients with early RA. Lysine acetylation is a dynamic
process that requires a tight balance between acetylases and deace-
tylases to maintain appropriate acetylation proﬁles required for
normal cellular function.22 Acetylation proﬁles are altered in a
variety of diseases and can be modulated by certain dietary com-
ponents in vivo.23 The microbiome has recently also been shown
to affect acetylation patterns in vivo.18 De novo acetylation of
lysine residues in hepatic and colonic proteins was seen following
colonisation of germ-free raised mice with microbiota from con-
ventionally raised mice.18 The observation that certain gut bacteria
inﬂuence host cells lysine acetylation is of potential relevance to
RA. Infections have long been linked to RA; the disease-modifying
drug sulfasalazine has an antibiotic effect, and the antibiotic doxy-
cycline has disease-modifying effects.23 Disease is attenuated in
arthritis animal models if they are raised in germ-free conditions
or treated with antibiotics while introduction of speciﬁc gut bac-
teria induces joint inﬂammation.24 25 However, the mechanisms
explaining these effects remain undeﬁned. Recently, Scher et al26
identiﬁed evidence of Prevotella copri in faeces from 75% of new
onset treatment-naive patients with RA, a signiﬁcantly higher per-
centage than found in patients with long-standing treated RA,
treated psoriatic arthritis and healthy controls. The signiﬁcance of
our ﬁnding of anti-AcVimentin antibodies in the sera of patients
with anti-CCP-positive RAwill need to be elucidated. However, it
Figure 3 Frequency of antibody positivity to different post-
translationally modiﬁed peptides in each outcome group. Anti cyclic
citrullinated peptide (CCP)-positive rheumatoid arthritis (RA) (checkered
bar), anti-CCP-negative RA (vertical lines bar), persistent non-RA arthritis
(black bar) and resolving arthritis (grey bar). (A) IgG reactivities:
statistically signiﬁcant differences in the percentages of patients with
positive antibodies were observed between patients with anti-CCP-positive
RA and the remaining groups for all peptides. (B) IgA reactivities:
statistically signiﬁcant differences in the frequency of anti-CitVimentin IgA
antibody reactivities seen between patients with anti-CCP-positive RA and
the remaining groups but not for the remaining post-translationally
modiﬁed peptides. ***p≤0.001. (C) Distribution of the number of
peptides recognised according to outcome group. The highest proportion
of patients with anti-CCP-positive RA recognised three peptides while the
highest proportions of patients in the remaining outcome groups did not
recognise any peptides.
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is possible that there may be a link between the microbiome, self-
antigen acetylation and autoimmunity. The test characteristics of
anti-AcVimentin antibodies are relatively poor for predicting the
development of anti-CCP-negative RA, suggesting that the identiﬁ-
cation of these antibodies is unlikely to be useful in this context.
Future work will need to address their role in predicting disease
severity and other clinically relevant outcomes in patients with RA.
Anticarbamylated protein antibodies have been identiﬁed in
the sera of patients with early RA of <2 years’ duration.8
Antibodies were present in 37% of ACPA-positive and 16% of
ACPA-negative patients.8 In a subsequent study from the same
group, anticarbamylated antibody positivity was assessed in two
large RA cohorts and mainly detected in the anti-CCP-positive
group, more consistent with our results.27 We show that 68.7%
of anti-CCP-positive and 3% of anti-CCP-negative patients with
RA have anti-CarVimentin antibodies. Differing frequencies
between studies may be explained by differing study designs,
sample sizes, disease durations and/or differences in antigens
used. While the antigen we used was a vimentin-derived peptide
of known sequence where homocitrulline was introduced at a
speciﬁc position, Shi et al used carbamylated fetal calf serum
(FCS). FCS contains multiple proteins, and a number of differ-
ent amino acids may be modiﬁed during the carbamylation reac-
tion, resulting in multiple potential epitopes. Furthermore,
carbamylation reactions require very speciﬁc reaction condi-
tions. Factors such as temperature, amount of cyanate used and
reaction duration will determine the number of lysine residues
that are carbamylated. Consequently, this may result in
Figure 4 Graphical representation of IgG antibody reactivity results. Patients with anti cyclic citrullinated peptide (CCP)-positive rheumatoid
arthritis (RA) showed a distinct antibody proﬁle that differed from that of the remaining outcome groups. This patient group had reactivities against
a higher number of peptides and the antibody levels against those peptides were also higher. Shaded squares represent positive tests: light grey,
low-level positivity (OD >98th percentile to 1.0); dark grey, medium positivity (OD >1.0–1.9); black, high positivity (OD >1.9). Each row represents
an individual patient, each column represents a peptide. Control, native unmodiﬁed vimentin peptide; CitVim, citrullinated vimentin peptide;
CarVim, carbamylated vimentin peptide; AcVim, acetylated vimentin peptide.
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generation of differing antigen epitopes in different reactions. In
contrast, by introducing homocitrulline in a speciﬁc position of
the peptide, we ensured that reactivity against a speciﬁc known
antigen was consistently tested.
While cross-reactivity between anticarbamylated protein anti-
bodies and ACPA is estimated at 30%,28 no association between
anticarbamylated antibody positivity and smoking or human
leucocyte antigen (HLA)-DRB alleles has been found, suggesting
that mechanisms underlying anticarbamylated antibody and
ACPA formation differ.27 We show a degree of cross-reactivity
between antibody families that is comparable to that of pub-
lished work. The existence of cross-reactive antibodies was also
suggested by the ﬁrst characterisation of anticarbamylated anti-
bodies where immunisation of rabbits with homocitrullinated
human albumin triggered anti-CCP2 and anti-MCV antibody
generation.10 Cross-reactivity between anticarbamylated ﬁbrino-
gen antibodies and ACPA in the sera of patients with RA has
recently been described.29 The fact that antibodies do not bind
single amino acids but rather a structural epitope formed of
many amino acids must be considered in this context. The
majority of cross-reactive antibodies likely occur because protein
regions that contain homocitrulline structurally resemble an
alternative protein region that contains citrulline.
A strength of our study is that the design of speciﬁc peptides
in which each modiﬁcation is introduced sequentially, together
with the results of the competition experiments, enabled us to
distinguish speciﬁc antibody reactivities. Inhibition experiments
showed limited cross-reactivity between antiacetylated, anticar-
bamylated and anticitrullinated vimentin peptide antibodies,
indicating that these are different antibody families. While
citrullinated antigens other than vimentin (eg, ﬁbrinogen) gener-
ate ACPA reactivity, for this work we chose a vimentin-derived
peptide as antigen. We reasoned that to maximise the yield of
novel autoantibodies identiﬁed, PTMs should be introduced on
the backbone of an already well-known autoantibody trigger.
This backbone was derived from the protein that is used in the
MCVassay (of known high sensitivity and speciﬁcity) and that is
present in RA joints.7 Furthermore, an epitope present in the
peptide we used is preferentially recognised by ACPA4 and
HLA-DRB1 binds with high afﬁnity to citrullinated vimentin
peptides generating T cell response,30 all of which led us to use
this as our candidate peptide backbone. Now that the presence
of antiacetylated antibodies has been established, reactivity
against other acetylated peptides and proteins should be assessed
to determine whether higher sensitivity and speciﬁcity to other
acetylated substrates exists. Future work should also be directed
towards identiﬁcation of acetylated proteins in diseased RA
joints.
In summary, these data suggest that, like citrullination, carba-
mylation and acetylation may be involved in the pathogenesis of
RA by triggering the generation of autoantibodies and/or by
generating targets for antibody responses in the rheumatoid
joint.
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